These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15705277)

  • 61. [The rise in fluoroquinolone-resistant Neisseria gonorrhoeae among people attending the Municipal Health Service's clinic for sexually transmitted diseases in Amsterdam, the Netherlands; cefotaxime now first-choice treatment for uncomplicated gonorrhoea].
    Kolader M; Peerbooms PG; Vader PC; van Bergen JE; Fennema JS; de Vries HJ
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2129-32. PubMed ID: 15553358
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay.
    Magooa MP; Müller EE; Gumede L; Lewis DA
    Int J Antimicrob Agents; 2013 Jul; 42(1):63-7. PubMed ID: 23623337
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enoxacin as one day oral treatment of men with anal or pharyngeal gonorrhoea.
    Bakhtiar M; Samarasinghe PL
    Genitourin Med; 1988 Dec; 64(6):364-6. PubMed ID: 3224972
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.
    Allen VG; Mitterni L; Seah C; Rebbapragada A; Martin IE; Lee C; Siebert H; Towns L; Melano RG; Low DE
    JAMA; 2013 Jan; 309(2):163-70. PubMed ID: 23299608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Susceptibility pattern of Neisseria gonorrhoeae to antimicrobial agents in Dar es Salaam.
    Mbwana J; Mhalu F; Mwakagile D; Masesa J; Moshiro C; Sandstrom E
    East Afr Med J; 1999 Jun; 76(6):330-4. PubMed ID: 10750520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ciprofloxacin-resistant gonorrhoea in South Africa.
    Moodley P; Sturm AW
    Lancet; 2005 Oct; 366(9492):1159. PubMed ID: 16198757
    [No Abstract]   [Full Text] [Related]  

  • 67. An evaluation of Neisseria gonorrhoeae antimicrobial susceptibility testing in the UK.
    Jain A; Cole MJ; Planche T; Ison CA
    J Clin Pathol; 2014 Nov; 67(11):1013-6. PubMed ID: 25078330
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gonococcal drug resistance and treatment of gonorrhoea in Nairobi.
    Perine PL; Biddle JW; Nsanze H; D'Costa LJ; Osaba AO; Widy-Wirski R
    East Afr Med J; 1980 Apr; 57(4):238-46. PubMed ID: 6771118
    [TBL] [Abstract][Full Text] [Related]  

  • 69. What is new with antibiotic-resistant gonorrhoea in Newcastle, England?
    Elawad BB; Narayanan M; Pattman RS; Sankar KN; Freeman R
    Int J STD AIDS; 2002 Dec; 13(12):805-8. PubMed ID: 12537730
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of gonorrhoea in Auckland, New Zealand: marked variation in prescriber adherence to treatment guidelines.
    Forster R; Ng D; Upton A; Franklin R; Thomas M
    Intern Med J; 2017 Jun; 47(6):640-648. PubMed ID: 28345188
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity.
    Lewis DA; Scott L; Slabbert M; Mhlongo S; van Zijl A; Sello M; du Plessis N; Radebe F; Wasserman E
    Sex Transm Infect; 2008 Oct; 84(5):352-5. PubMed ID: 18596070
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antimicrobial susceptibility and molecular epidemiology of Neisseria gonorrhoeae in Germany.
    Horn NN; Kresken M; Körber-Irrgang B; Göttig S; Wichelhaus C; Wichelhaus TA;
    Int J Med Microbiol; 2014 Jul; 304(5-6):586-91. PubMed ID: 24801146
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Australian Gonococcal Surveillance Programme, 1 April to 30 June 2015.
    Lahra MM; Enriquez RP;
    Commun Dis Intell Q Rep; 2015 Dec; 39(4):E628-30. PubMed ID: 26779739
    [No Abstract]   [Full Text] [Related]  

  • 74. A double trial of amoxycillin in the treatment of gonorrhoea.
    Thin RN; Symonds MA; Shaw EJ; Wong J; Hopper PK; Slocombe B
    Br J Vener Dis; 1977 Apr; 53(2):118-20. PubMed ID: 322821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea.
    Barbee LA; Kerani RP; Dombrowski JC; Soge OO; Golden MR
    Clin Infect Dis; 2013 Jun; 56(11):1539-45. PubMed ID: 23408680
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Repurposing an old drug: aztreonam as a new treatment strategy for gonorrhoea.
    Davido B; Dinh A; Senard O; Calin R; Makhloufi S; Salomon J
    J Antimicrob Chemother; 2017 May; 72(5):1466-1468. PubMed ID: 28137938
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of single dose ciprofloxacin in the treatment of rectal and pharyngeal gonorrhoea.
    Coker DM; Ahmed-Jushuf I; Arya OP; Chessbrough JS; Pratt BC
    J Antimicrob Chemother; 1989 Aug; 24(2):271-2. PubMed ID: 2793651
    [No Abstract]   [Full Text] [Related]  

  • 78. National standards for the management of gonorrhoea.
    FitzGerald M; Bedford C
    Int J STD AIDS; 1996 Jul; 7(4):298-300. PubMed ID: 8876366
    [No Abstract]   [Full Text] [Related]  

  • 79. The diagnosis of oropharyngeal gonorrhoea.
    Barlow D
    Genitourin Med; 1997 Feb; 73(1):16-7. PubMed ID: 9155549
    [No Abstract]   [Full Text] [Related]  

  • 80. Editorial commentary: persistent gonococcal DNA: artifact or real? Further insights into the biology of a remarkable pathogen.
    Zenilman JM
    Clin Infect Dis; 2015 Feb; 60(4):564-5. PubMed ID: 25371492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.